BMY · Program file
Cobenfy
Bristol-Myers Squibb Company (BMY)
When did Bristol-Myers Squibb Company say Cobenfy results would come?
On , Bristol-Myers Squibb Company wrote in its SEC Form 8-K: “2027” (Source)
Last checked: .
Watch this program: confirm your email to start one daily alert digest.
Program file
- Name as filed
- Cobenfy
- Other names in filings
- ADEPT
- Indication in the filing
- AD Psychosis
- Trials named in the same filing
- None listed
- Latest timing wording
- “2027”
- Source
- 8-K · filed · SEC accepted · accession 0000014272-26-000018 · SEC original
- Last checked
- Correction
- : The SEC acceptance time shown for Cobenfy (BMY) on its program page was 2026-07-30T15:05:39Z, four hours later than the time in SEC's own header for the filing (8-K, accession 0000014272-26-000018, filed 2026-07-30). It was shown from 2026-10-12, when the program file was published. Replaced with the header time, 2026-07-30T11:05:39Z. Checked on 2026-10-12 by reading the filing's SEC header; the other 14 program files matched. The review label is unchanged: the acceptance time is metadata, and the quoted wording and its source are unchanged. Earlier daily hashes and records are not changed; this correction is a new record. SEC header · Evidence · All corrections
Program BMY-cobenfy.